Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. Issue 7 (6th July 2022)

• Record Type: Journal Article
• Authors: Shui, Irene M.; Liu, Xiao Qiao; Zhao, Qing; Kim, Seung Tae; Sun, Yuan; Yearley, Jennifer H.; Choudhury, Tasmiah; Webber, Andrea L.; Krepler, Clemens; Cristescu, Razvan; Lee, Jeeyun
• Is Part Of: Journal for immunotherapy of cancer. Volume 10:Issue 7(2022)
• Publication Date: 2022-07-06
• Subjects: Melanoma -- Programmed Cell Death 1 Receptor -- Biomarkers, Tumor; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2022-004879
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: Immunotherapies targeting programmed cell death-1 (PD-1) and its ligands have improved clinical outcomes for advanced melanoma. However, many tumors exhibit primary resistance or acquire secondary resistance after an initial positive response. The mechanisms of resistance are not well understood, and no validated predictive biomarkers are available. This exploratory study aimed to characterize baseline differences and molecular changes arising during treatment in acral and mucosal melanomas that exhibited primary or secondary resistance to anti-PD-1 monotherapy. Methods: This was an observational retrospective study of 124 patients who had been treated for metastatic acral or mucosal melanoma with anti-PD-1 monotherapy. Tumor samples were collected at baseline (all patients) and post-treatment (resistant tumors only) and were assayed by immunohistochemistry, whole-exome sequencing, and RNA sequencing. Results: At baseline, more non-progressor than resistant tumors exhibited expression of PD-L1, immune cell infiltration, and high tumor mutational burden (TMB); baseline PD-L1 expression was also more common in secondary-resistant than in primary-resistant tumors as well as in late versus early secondary-resistant tumors. Non-progressor tumors also had higher median baseline expression of an 18-gene T cell-inflamed gene expression profile (Tcellinf GEP). Among resistant tumors, the proportion of PD-L1-positive melanomas and the expression of the Tcellinf GEP mRNA signature increased during treatment, while the expression of mRNA signatures related to WNT and INFA1 signaling decreased. There was evidence for greater changes from baseline in secondary-resistant versus primary-resistant tumors for some markers, including expression of RAS-related and WNT-related mRNA signatures and density of CD11c + and FOXP3 + T cells. Greater changes in CD11c + cell density were observed in early compared with late secondary-resistant tumors. Conclusions: Our findings suggest that Tcellinf GEP and PD-L1 expression, TMB, immune cell infiltration, and RAS and WNT signaling warrant further investigation as potential mechanisms and/or biomarkers of anti-PD-1 therapy resistance in acral and mucosal melanomas. Confirmation of these findings in larger populations is needed.